Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses

Read more at globenewswire.com